Type 1 Diabetes
Conditions
Brief summary
A number of arguments suggest that the deterioration in high density lipoproteins (HDL) functioning may worsen with the development of nephropathy during type 1 diabetes (T1D). The objective of this study will be to investigate to what extent nephropathy in T1D patients in the microalbuminuria and macroalbuminuria stages, compared to T1D patients without nephropathy, is associated with an alteration in HDL functionality and changes in HDL size and composition (lipids with detailed study of phosphates and sphingolipids, main lipoproteins, inflammatory markers).
Interventions
BIOLOGICALBlood samples
5 EDTA tubes of 7ml and 1 dry tube of 7 ml taken on an empty stomach
BIOLOGICALUrine sample
Urine sample on an empty stomach
Sponsors
Centre Hospitalier Universitaire Dijon
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
INCLUSION CRITERIA GROUP C (CONTROLS) : * age \> 18 years * a person who has given oral consent * Non-diabetics * Fasting plasma glucose \< 6.10 mmol/L (1.1 g/L) * Triglyceridemia \< 1.7 mmol/L (1.5 g/l) * HDL-C concentration \> 1.30 mmol/L (for women and 1.03 mmol/L for men) * Glomerular filtration flow rate \> 90 mL/min/1.73m2 (These thresholds correspond to the standard thresholds for these parameters) INCLUSION CRITERIA GROUP T1D-N (WITH NORMAL ALBUMINURIA) : * age \> 18 years * a person who has given oral consent * Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l) * HbA1c between 6 and 9%. * normal albuminuria (albumin/creatinine ratio \< 2.5 mg/mmol in men and \< 3.5 in women) * glomerular filtration rate \> 90 mL/min/1.73m2 INCLUSION CRITERIA GROUP T1D-MICRO (WITH MICROALBUMINURIA) * age \> 18 years * a person who has given oral consent * Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l) * HbA1c between 6 and 9%. * Microalbuminuria (albumin/creatinine ratio \> 2.5 mg/mmol in men and \> 3.5 in women, and \< 30 mg/mmol) * glomerular filtration rate \> 90 mL/min/1.73m2 INCLUSION CRITERIA GROUP T1D-MACRO (WITH MACROALBUMINURIA) * age \> 18 years * a person who has given oral consent * Diabetic type 1 (based on the patient's clinical history and/or the presence of anti-glutamate decarboxylase autoantibodies and/or plasma C-peptide less than 0.5 ng/l) * HbA1c between 6 and 9%. * Macroalbuminuria (albumin/creatinine ratio \> 30 mg/mmol) * glomerular filtration rate \> 45 mL/min/1.73m2
Exclusion criteria
* Protected adult * Patient not affiliated to a social security scheme * Pregnant or breastfeeding woman * Drugs interfering with lipid metabolism outside insulin for DT1 : hypolipidemic (only for patients included in the DT1-micro group), corticosteroid, estroprogestogens, retinoic acid, antiproteases. * BMI \> 30 kg/m2
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Ability to induce cholesterol efflux | inclusion | amount of cholesterol captured from cells expressed as %. |
| Nitric oxide synthesis | inclusion | variation in the presence of HDL compared to the basal state, i.e. in the absence of HDL |
| Anti-inflammatory effect | inclusion | variation in the expression of adhesion molecules (VCAM-1 \[vascular cell adhesion molecule 1\], ICAM-1 \[InterCellular Adhesion Molecule 1\] and E selectin) under the influence of TNF-alpha \[Tumor Necrosis Factor alpha\] in the presence of HDL compared to the absence of HDL. |
Countries
France
Outcome results
None listed